Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer

Minkyu Jung; Yanping Yang; Jaclyn E. McCloskey; Marjan Zaman; Yogindra Vedvyas; Xianglan Zhang; Dessislava Stefanova; Katherine D. Gray; Irene M. Min; Raza Zarnegar; Yoon Young Choi; Jae Ho Cheong; Sung Hoon Noh; Sun Young Rha; Hyun Cheol Chung; Moonsoo M. Jin

doi:10.1016/j.omto.2020.08.009

Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer

Minkyu Jung, Yanping Yang, Jaclyn E. McCloskey, Marjan Zaman, Yogindra Vedvyas, Xianglan Zhang, Dessislava Stefanova, Katherine D. Gray, Irene M. Min, Raza Zarnegar, Yoon Young Choi, Jae Ho Cheong, Sung Hoon Noh, Sun Young Rha, Hyun Cheol Chung, Moonsoo M. Jin

Department of Internal Medicine

Research output: Contribution to journal › Article › peer-review

23 Citations (Scopus)

Abstract

In this study, we demonstrated the therapeutic potential of CAR T cells targeting ICAM-1 in preclinical models of systemic and intraperitoneal metastases of gastric cancer. A combination with paclitaxel or armoring CAR T cells with inducible IL-12 was found to significantly enhance the treatment effect of CAR T cells.

Original language	English
Pages (from-to)	587-601
Number of pages	15
Journal	Molecular Therapy - Oncolytics
Volume	18
DOIs	https://doi.org/10.1016/j.omto.2020.08.009
Publication status	Published - 2020 Sept 25

Bibliographical note

Funding Information:
This work was supported by NIH grant R01CA217059 , Emerson Collective Cancer Research Fund (ECCRF 191824-01 ), a sponsored research grant ( AffyImmune ), and by an institutional grant ( MI3 , Weill Cornell Medicine ). We thank Dr. Eric von Hofe for critical reading of this manuscript.

Funding Information:
This work was supported by NIH grant R01CA217059, Emerson Collective Cancer Research Fund (ECCRF 191824-01), a sponsored research grant (AffyImmune), and by an institutional grant (MI3, Weill Cornell Medicine). We thank Dr. Eric von Hofe for critical reading of this manuscript.

Publisher Copyright:
© 2020 The Author(s)

All Science Journal Classification (ASJC) codes

Molecular Medicine
Oncology
Cancer Research
Pharmacology (medical)

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.omto.2020.08.009

Cite this

Jung, M., Yang, Y., McCloskey, J. E., Zaman, M., Vedvyas, Y., Zhang, X., Stefanova, D., Gray, K. D., Min, I. M., Zarnegar, R., Choi, Y. Y., Cheong, J. H., Noh, S. H., Rha, S. Y., Chung, H. C., & Jin, M. M. (2020). Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer. Molecular Therapy - Oncolytics, 18, 587-601. https://doi.org/10.1016/j.omto.2020.08.009

@article{aaa29547cbd345329900660b1b305d55,

title = "Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer",

abstract = "In this study, we demonstrated the therapeutic potential of CAR T cells targeting ICAM-1 in preclinical models of systemic and intraperitoneal metastases of gastric cancer. A combination with paclitaxel or armoring CAR T cells with inducible IL-12 was found to significantly enhance the treatment effect of CAR T cells.",

author = "Minkyu Jung and Yanping Yang and McCloskey, {Jaclyn E.} and Marjan Zaman and Yogindra Vedvyas and Xianglan Zhang and Dessislava Stefanova and Gray, {Katherine D.} and Min, {Irene M.} and Raza Zarnegar and Choi, {Yoon Young} and Cheong, {Jae Ho} and Noh, {Sung Hoon} and Rha, {Sun Young} and Chung, {Hyun Cheol} and Jin, {Moonsoo M.}",

note = "Funding Information: This work was supported by NIH grant R01CA217059 , Emerson Collective Cancer Research Fund (ECCRF 191824-01 ), a sponsored research grant ( AffyImmune ), and by an institutional grant ( MI3 , Weill Cornell Medicine ). We thank Dr. Eric von Hofe for critical reading of this manuscript. Funding Information: This work was supported by NIH grant R01CA217059, Emerson Collective Cancer Research Fund (ECCRF 191824-01), a sponsored research grant (AffyImmune), and by an institutional grant (MI3, Weill Cornell Medicine). We thank Dr. Eric von Hofe for critical reading of this manuscript. Publisher Copyright: {\textcopyright} 2020 The Author(s)",

year = "2020",

month = sep,

day = "25",

doi = "10.1016/j.omto.2020.08.009",

language = "English",

volume = "18",

pages = "587--601",

journal = "Molecular Therapy - Oncolytics",

issn = "2372-7705",

publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer

AU - Jung, Minkyu

AU - Yang, Yanping

AU - McCloskey, Jaclyn E.

AU - Zaman, Marjan

AU - Vedvyas, Yogindra

AU - Zhang, Xianglan

AU - Stefanova, Dessislava

AU - Gray, Katherine D.

AU - Min, Irene M.

AU - Zarnegar, Raza

AU - Choi, Yoon Young

AU - Cheong, Jae Ho

AU - Noh, Sung Hoon

AU - Rha, Sun Young

AU - Chung, Hyun Cheol

AU - Jin, Moonsoo M.

N1 - Funding Information: This work was supported by NIH grant R01CA217059 , Emerson Collective Cancer Research Fund (ECCRF 191824-01 ), a sponsored research grant ( AffyImmune ), and by an institutional grant ( MI3 , Weill Cornell Medicine ). We thank Dr. Eric von Hofe for critical reading of this manuscript. Funding Information: This work was supported by NIH grant R01CA217059, Emerson Collective Cancer Research Fund (ECCRF 191824-01), a sponsored research grant (AffyImmune), and by an institutional grant (MI3, Weill Cornell Medicine). We thank Dr. Eric von Hofe for critical reading of this manuscript. Publisher Copyright: © 2020 The Author(s)

PY - 2020/9/25

Y1 - 2020/9/25

N2 - In this study, we demonstrated the therapeutic potential of CAR T cells targeting ICAM-1 in preclinical models of systemic and intraperitoneal metastases of gastric cancer. A combination with paclitaxel or armoring CAR T cells with inducible IL-12 was found to significantly enhance the treatment effect of CAR T cells.

AB - In this study, we demonstrated the therapeutic potential of CAR T cells targeting ICAM-1 in preclinical models of systemic and intraperitoneal metastases of gastric cancer. A combination with paclitaxel or armoring CAR T cells with inducible IL-12 was found to significantly enhance the treatment effect of CAR T cells.

UR - http://www.scopus.com/inward/record.url?scp=85090716989&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85090716989&partnerID=8YFLogxK

U2 - 10.1016/j.omto.2020.08.009

DO - 10.1016/j.omto.2020.08.009

M3 - Article

AN - SCOPUS:85090716989

SN - 2372-7705

VL - 18

SP - 587

EP - 601

JO - Molecular Therapy - Oncolytics

JF - Molecular Therapy - Oncolytics

ER -

Chimeric Antigen Receptor T Cell Therapy Targeting ICAM-1 in Gastric Cancer

Abstract

Bibliographical note

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this